® Best Care for Everyone GABAPENTIN – SAFE PRESCRIBING – DOES THE DOSE FIT? 4PROVIDE CLEAR DOSING AND TITRATION INSTRUCTIONS WHEN INITIATING GABAPENTIN 4DOSE AS PER RENAL FUNCTION 4DO NOT STOP ABRUPTLY IF USED FOR EPILEPSY 4USE WITH CAUTION IN PEOPLE AT RISK OF FALLS AND WARN ABOUT SEDATION 4INVESTIGATE SERIOUS ADVERSE EFFECTS Gabapentin is an anticonvulsant that is used for certain types of epilepsy in patients who have not achieved adequate control with standard anti-epileptic drugs (AEDs). Gabapentin does not require serum level monitoring and does not alter the serum concentration of other AEDs.1 In some patients, gabapentin can also relieve neuropathic pain (e.g. diabetic peripheral neuropathy), and skin conditions associated with pain such as post-herpetic neuralgia. Gabapentin is funded where tricyclic antidepressants are either ineffective or not tolerated.2 Amitriptyline and gabapentin can be used in combination if the patient has an inadequate response to either drug at the maximum tolerated dose. Gabapentin is also useful for post-operative analgesia3 and for migraine prophylaxis (unapproved indication). The effective dose range for epilepsy is usually 900 to 1800mg per day;1 however, some patients may require the maximum dose of 1200mg three times daily (3600mg per day).4 PROVIDE CLEAR DOSING AND TITRATION INSTRUCTIONS WHEN INITIATING GABAPENTIN Note: Antacids can reduce the efficacy of gabapentin when taken at the same time.9 Inform patients to take antacids at least 2 hours before or after taking gabapentin.4 Gabapentin has a short half-life and has to be dosed three to four times daily. To reduce troublesome adverse effects that can occur upon initiation (e.g. somnolence, dizziness and ataxia), start with an evening dose, and then gradually up-titrate the dose as tolerated. Some patients may take up to 4 weeks to achieve the optimal dose, requiring one week at each dose level. Slow dose titration of gabapentin5 For neuropathic pain, it is important to test the benefit of gabapentin at each dose level, before progressing to higher doses. Benefit may not necessarily be enhanced with higher doses.6 The optimal dose varies widely between patients from 100mg at night up to 1200mg three times per day, depending on patient age and other medical conditions. Consider other agents after 4 to 6 weeks if gabapentin does not provide adequate relief,7 or if side effects become unacceptable. The efficacy of gabapentin for neuropathic pain has been scrutinised over recent years.6 The Cochrane Collaboration has concluded that gabapentin provides substantial pain relief in about a third of people who take it for neuropathic pain.8 DOSE AS PER RENAL FUNCTION Dose adjustments are necessary for patients with poor renal function because gabapentin is cleared renally. Refer to the following table for maximum dosing recommendations.1,4 Gabapentin dosing recommendations1 Renal function (eGFR mL/min/1.73m2) Total daily dose (mg/day)* Time Dose Greater than 80 900-3600 Day 1-3 300mg at night 50-79 600-1800 Day 4-7 300mg twice daily 30-49 300-900 Week 2 300mg three times daily 15-29 150#-600 Week 3 600mg three times daily Less than 15 150#-300 Slower titration (e.g. in 100mg increments) is especially beneficial for the elderly or for patients with renal impairment or multiple medical problems.1 *To be administered as a three times daily regimen # To be administered as 300mg on alternate days Note: Dose adjustments are not required for patients with impaired hepatic function.1 ➥ continued 1 Best Care for Everyone 2 GABAPENTIN DO NOT STOP ABRUPTLY IF USED FOR EPILEPSY Abrupt withdrawal of anticonvulsants may precipitate a seizure; if gabapentin is to be discontinued, this should be done gradually over at least a week.1 Other adverse events that have been observed following the abrupt discontinuation of gabapentin include anxiety, insomnia, nausea and sweating.1 Due to the short half-life of gabapentin, in order to minimise the risk of breakthrough seizures, ensure the patient understands that they should not allow more than 12 hours to elapse between regular doses.1 Note: Gabapentin may worsen or exacerbate absence and myoclonic seizures and should not be given to these patients, or to patients with mixed seizure disorders that involve absence seizures.1,4 USE WITH CAUTION IN PEOPLE AT RISK OF FALLS AND WARN ABOUT SEDATION The most frequent side effects associated with gabapentin are somnolence and dizziness.1 For this reason, elderly patients (and their caregivers) must be informed that these effects can increase the risk of falls.6 Patients should be advised not to drive or operate dangerous machinery until it is known whether gabapentin affects their ability to do so safely.1 The degree of drowsiness and sedation will depend on the individual. Patients should be warned about these risks when prescribing. Alcohol can further increase the drowsiness associated with gabapentin, but to varying degrees depending on the individual.4 Although alcohol does not affect the efficacy of gabapentin, it can increase the seizure risk in patients with epilepsy. Most people with epilepsy can have one or two units of alcohol without increasing the chances of having a seizure.4 Note: Gabapentin has been reported to enhance the analgesic effects of morphine. This combination can actually benefit patients in the post-operative setting because lower doses of morphine may be sufficient. Morphine can also increase the bioavailability of gabapentin, so if patients are maintained on gabapentin (e.g. for epilepsy) and require morphine, observe them closely for drowsiness. Dose reductions of gabapentin and/or morphine may be necessary.1 INVESTIGATE SERIOUS ADVERSE EFFECTS Rash Patients taking AEDs, including gabapentin, are at risk of drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. This is a rare, but potentially lifethreatening condition. Patients should be advised to inform their doctor immediately if they notice any signs of hypersensitivity such as fever, lymphadenopathy or rash. Gabapentin should be discontinued if hypersensitivity is confirmed.1 Suicidality As with other AEDs, gabapentin may increase the risk of suicidal thoughts or behaviour. Patients should be monitored for the emergence or worsening of depression, suicidal thoughts, or unusual changes in mood or behaviour. These may occur as early as one week after starting treatment and continue for the duration of treatment. Patients, caregivers and families should be advised to be alert to these symptoms and report them to the prescriber if they occur.1 Note: Other side-effects associated with gabapentin include abnormal liver function tests, taste disturbance, headache and weight gain. ➥ continued Best Care for Everyone GABAPENTIN ACKNOWLEDGEMENTS We wish to thank Michal Kluger, Pain Specialist, Waitemata Pain Services and and Claire McGuinniety, Pharmacist, Waitemata DHB for their valuable contribution to this bulletin. REFERENCES 1. Arrow Pharmaceuticals (NZ) Limited. Arrow- Gabapentin capsules datasheet. 17-05-12. http://www.medsafe.govt.nz/profs/datasheet/a/ arrowgabapentincap.pdf (Accessed 21-04-13) 2. Pharmaceutical Management Agency, New Zealand (PHARMAC) Special Authority form Gabapentin SA1071 May 2013 http://www.pharmac.govt. nz/2013/05/01/SA1071.pdf (Accessed 29-4-13) 3. Straube S, Derry S, Moore RA, Wiffen PJ, McQuay HJ. Single dose oral gabapentin for established acute postoperative pain in adults. Cochrane Database of Systematic Reviews 2010, Issue 5. Art. No.: CD008183. DOI: 10.1002/14651858.CD008183.pub2. http://onlinelibrary.wiley.com/ doi/10.1002/14651858.CD008183.pub2/pdf (Accessed 19-04-13) 4. The New Zealand Formulary, Gabapentin. http://www.nzf.org.nz/nzf_2629. html?searchterm=gabapentin (Accessed 21-04-13) 5. Kluger M. Pain specialists website, gabapentin (updated 10-04-11) http://pain-specialists.com/index.php?option=com_content&view=article& id=120:gabapentin&catid=66:gabapentin&Itemid=11 (Accessed 08-05-13) 6. Best Practice Advisory Centre. New evidence shows less benefit of gabapentin for neuropathic pain. Best Practice Journal 2010;28:54-5 http://www.bpac.org.nz/magazine/2010/june/snippets.asp#gabapentin (Accessed 19—4-13) 7. Ritchie ED, Cameron F. Pain management guidelines book. National Health Service Tayside 2010. http://school.tayside-anaesthesia.net/ resources/4/pain%20guidelines%202010.pdf (Accessed 08-05-13) 8. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No.: CD007938. DOI: 10.1002/14651858.CD007938.pub2. http://onlinelibrary.wiley.com/ doi/10.1002/14651858.CD007938.pub2/pdf (Accessed 19-04-13) 9. Yagi T, Naito T, Mino YU et al. Impact of concomitant antacid administration on gabapentin plasma exposure and oral bioavailability in healthy adult subjects. Drug Metabolism and Pharmacokinetics 2012;27(2):248-54 http://www.ncbi.nlm.nih.gov/pubmed/22240839 (Accessed 22-04-13) For further information on other high-risk medicines visit our website at: www.saferx.co.nz No: 0182-01-109, Issued: July 2013, Review: July 2015 DISCLAIMER: This information is provided to assist primary care health professionals with the use of prescribed medicines. Users of this information must always consider current best practice and use their clinical judgement with each patient. This information is not a substitute for individual clinical decision making. Issued by the Quality Use of Medicines Team at Waitemata District Health Board, email: [email protected] 3
© Copyright 2024